Coeptis Therapeutics Holdings, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
ZSQR$2.30-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended | ||
|---|---|---|
| September 30, 2025 | September 30, 2024 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(10,654,290) | $(7,865,647) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 885,909 | 750,633 |
| Right of use asset amortization | 30,680 | 28,018 |
| Amortization of debt discount | 545,635 | 150,000 |
| Stock based compensation | 1,001,787 | 805,347 |
| Shares issued for non-employee services | 2,722,570 | 1,149,600 |
| Warrants issued for services | 824,295 | 8,150 |
| Change in fair value of derivative liability | (906,429) | – |
| Change in fair value of derivative liability warrants | 50,250 | (235,125) |
| Gain on writedown of liability | (159,035) | – |
| Loss on shares issued for conversion of debt | – | 77,250 |
| Loss on writedown of derivative liability | 135,054 | – |
| Unrealized loss on marketable securities | 178,302 | – |
| (Increase) decrease in: | ||
| Accounts receivable | (82,500) | – |
| Interest receivable | (3,541) | (152,104) |
| Prepaid assets | (56,233) | 156,880 |
| Increase (decrease) in: | ||
| Accounts payable | (482,127) | (285,456) |
| Accrued expenses | (410,642) | 227,868 |
| Customer deposit | (388,496) | – |
| Right of use liability | (31,315) | (28,157) |
| Other current liabilities | (115,000) | – |
| NET CASH USED IN OPERATING ACTIVITIES | (6,915,126) | (5,212,743) |
| INVESTING ACTIVITIES | ||
| Increase in subscription receivable in exchange for cash | – | (100,000) |
| NET CASH USED IN INVESTING ACTIVITIES | – | (100,000) |
| FINANCING ACTIVITIES | ||
| Proceeds from notes payable | 990,000 | 1,850,000 |
| Repayment of notes payable | (218,750) | (587,500) |
| Shares issued for SEPA | 2,039,195 | – |
| Shares issued for cash | 3,024,633 | – |
| Warrants issued for cash | 650 | 500,000 |
| Preferred stock offering | 5,455,000 | 3,218,561 |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 11,290,728 | 4,981,061 |
| NET INCREASE (DECREASE) IN CASH | 4,375,602 | (331,682) |
| CASH AT BEGINNING OF PERIOD | 532,885 | 1,469,134 |
| CASH AT END OF PERIOD | $4,908,487 | $1,137,452 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES | ||
| Interest paid | $6,579 | $6,579 |
| Taxes paid | $– | $– |
| SUPPLEMENTAL NON-CASH DISCLOSURES | ||
| Subscriptions receivable | $2,100,368 | $4,100,000 |
| Shares issued for the conversion of debt | $2,396,478 | $868,750 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.